Revised. Amendments from Version 1
==================================

It is now explicitly stated that the IV ceftriaxone was discontinued when the Xpert result came back at positive. It is now explicitly stated that there was no evidence of rifampicin resistance from the Xpert result. A sentence has been added noting that is takes approximately 2 weeks for the full effects of enzyme induction by rifampicin to be mounted. A sentence has been added highlighting the need for a lipid meal to be taken prior to lumefantrine to optimise absorption. The units for CSF opening pressure has been changed from cm H20 to cm CSF. A sentence has been added detailing planned follow up and adherence counselling provided. A paragraph has been added how future research in this important area may be conducted. Re: " *Is it common to present with TB meningitis five months into therapy where there has been apparent adherence?*" There is no data about the likelihood of TBM after initiation treatment for TB-meningitis. On effective quadruple anti-TBs with good adherence this is rare. However, this patient may not have been on effective quadruple anti-TBs as he reported poor adherence to his anti-tuberculous medications. In addition, baseline INR-resistance rates are 5-10% in Uganda but not routinely tested for; in patients with disseminated TB with baseline INH-resistance only PZA is effectively reaching the CNS at decent levels (RIF and ETH poor penetration). We also know that HIV-status is the strongest predictor of poor outcomes in PTB treatment and HIV is likely to negatively impact of PK achievements. LSHTM-MRC-UVRI Uganda Research Unit, Entebbe, Uganda has been listed as an additional affiliation for Fiona V. Cresswell.

Introduction
============

In 2016, 10.4 million cases of tuberculosis (TB) were reported globally ^[@ref-1]^. Tuberculous meningitis (TBM) accounts for 1--5% of these ^[@ref-2]^. Although TBM can occur in immunocompetent persons, the disease disproportionately affects persons living with HIV and children. Malaria also continues to be a global public health threat. In 2016, an estimated 216 million cases occurred, with 90% of those in Africa ^[@ref-3]^. Due to marked epidemiological overlap in the global burden of TB and malaria, co-infection does occur. In an Angolan retrospective study of 1,906 TB inpatients (37% HIV-infected), *Plasmodium falciparum* co-infection occurred in 38% during hospitalization ^[@ref-4]^.

TBM/malaria co-infection poses a number of management challenges. Rifampicin, the cornerstone for drug-sensitive TB treatment, is a potent enzyme inducer that increases the expression of several hepatic cytochrome P450 (CYP450) enzymes, including CYP2A6, CYP2B6, CYP2C, and CYP3A isoenzymes, as well as the efflux drug transporter P-glycoprotein ^[@ref-5]^. Peak enzyme induction due to rifampicin is mounted \~ 2 weeks post rifampicin initiation. This induction alters the pharmacokinetics of drugs metabolized by these pathways, reducing plasma concentrations of several anti-malarial medications, including artemisinin-based drugs, quinine and atovaquone/proguanil. In HIV/TBM/malaria co-infection, there are additional interactions between anti-retroviral therapy (ART) and anti-malarial medications ^[@ref-6]^.

Here; we present the case of a hospitalized HIV-infected adult with HIV/TBM/malaria co-infection, highlighting important diagnostic and pharmacokinetic challenges.

Case report
===========

An HIV-infected 32-year-old male presented to Mulago National Referral Hospital, Uganda with a 2-week history of headache with fevers and a 1-day history of confusion ( [Figure 1](#f1){ref-type="fig"}). He had been on ART (zidovudine, lamivudine, efavirenz) and co-trimoxazole prophylaxis for 5 years. 5 months prior, he was diagnosed with pulmonary TB by positive sputum Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA). He had completed 2 months of induction TB therapy (rifampicin, isoniazid, ethambutol, pyrazinamide) and was 3 months into continuation phase (rifampicin, isoniazid). He endorsed poor adherence to both ART and anti-tuberculous medications.

![Clinical presentation timeline.](wellcomeopenres-3-16387-g0000){#f1}

On examination, the patient was febrile (38.6°C). His blood pressure was 112/71 mmHg, pulse 94 beats/minute, respiratory rate 48, and oxygen saturation 98%. He was wasted, dehydrated, and had overt rigors. His Glasgow Coma Scale was 14/15 with nuchal rigidity and positive Kernig's sign. Cranial nerves were intact. He had normal tone and power in all limbs. A clinical diagnosis of HIV-associated meningitis was suspected and he was recruited into the 'Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related Meningitis' study (registration: [ISRCTN42218549](http://www.isrctn.com/ISRCTN42218549)). Whilst awaiting further investigations, he received empiric therapy of ceftriaxone 2 g twice daily for possible bacterial meningitis.

A finger stick cryptococcal antigen lateral flow assay (CrAg LFA) (IMMY, Norman, Oklahoma, USA) was negative. Liver and renal function tests were normal. Cerebrospinal fluid (CSF) opening pressure was elevated to 33 cm CSF (normal \<20 cm CSF), CSF white cells 590 /µl, protein 419 mg/dl (normal range 15--45 mg/dl), CSF lactate 9.5 mmol/L (normal range \<2.5 mmol/l). CSF glucose was unavailable. *Mycobacterium tuberculosis* in CSF was confirmed on Xpert MTB/RIF Ultra; there was no evidence of rifampicin resistance. On day 2, he was initiated on dexamethasone at 0.4 mg/kg/day and induction TB-medications were re-commenced (rifampicin, isoniazid, ethambutol, pyrazinamide) for TBM. The IV ceftriaxone was stopped, his ART was continued. He continued to spike high-grade fevers (39.6°C.) with tachycardia (pulse 118 beats/min). A peripheral blood smear showed *P. falciparum* parasites (1+ trophozoites), despite a negative malaria histidine rich protein-2 (PfHPR2)-based rapid diagnostic test (Malaria *Plasmodium falciparum* Rapid Test Cassette, Vaxpert, Florida, USA). Given his ongoing neurological symptoms, which could be compatible with cerebral malaria, the decision was made to treat for severe malaria. Drug-drug interactions (DDIs) between rifampicin and artemisinin compounds, and rifampicin and quinine are recognized ( [Table 1](#T1){ref-type="table"}); a decision was made to treat with IV artesunate as the most efficacious anti-malarial for severe malaria ^[@ref-6]^. He received three doses of IV artesunate (3 mg/kg), after which a repeat peripheral blood smear showed no malaria parasites. He then completed 3 days of oral artemether/lumefantrine. His fevers subsided on day 6. He was discharged on day 8; medication adherence counselling was provided for the patient and his guardian and outpatient follow-up was arranged for the following week.

###### Summary table of anti-malarial drug interactions with anti-tuberculous and anti-retroviral therapy.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Anti-malarial\         Clinical indication (WHO\          Recommended dose\                     Drug metabolism/excretion in\                       Potential interactions and\                               Potential Interactions\
  agents for\            Malaria guidelines) ^[@ref-6]^     and duration ^[@ref-6],\ [@ref-10]^   healthy adults ^[@ref-10]^                          modification with concurrent\                             and modification with\
  treatment &\                                                                                                                                        rifampicin ^[@ref-5],\ [@ref-6],\ [@ref-9],\ [@ref-11]^   concurrent ARVs ^[@ref-6],\ [@ref-10],\ [@ref-12]^
  prophylaxis                                                                                                                                                                                                   
  ---------------------- ---------------------------------- ------------------------------------- --------------------------------------------------- --------------------------------------------------------- ----------------------------------------------------
  Amodiaquine            1\. Uncomplicated\                 10 (7.5--15) mg/kg/day\               Rapidly converted via\                              No significant drug interaction\                          [EFV,NVP,AZT/ZVD]{.ul}: ↑plasma\
                         *P. falciparum* malaria\           once a day for 3 days.                CYP2C8, to active metabolite\                       data.                                                     conc. &↑LFTS; ↓AUC & risk\
                         in combination with\                                                     desethylamodiaquine. t ~1/2~ of\                                                                              of hepatotoxicity; increased\
                         artesunate.\                                                             amodiaquine ranges from 3--12 hrs,\                                                                           risk of neutropenia\
                         \                                                                        while the active metabolite can vary\                                                                         respectively. Avoid use.\
                         2. In combination with\                                                  from 6--18 days.                                                                                              [PIs]{.ul}: Potential ↑plasma\
                         sulfadoxine-pyrimethamine\                                                                                                                                                             conc. Monitor use closely.
                         for seasonal malaria\                                                                                                                                                                  
                         chemo-prevention in young\                                                                                                                                                             
                         children                                                                                                                                                                               

  Artemether/\           1\. Uncomplicated\                 Oral Artemeter:\                      Converted via CYP3A4/5 (primary),\                  Concurrent use results in\                                [EFV, NVP]{.ul}: ↓plasma conc.\
  lumefantrine           *P. falciparum* malaria as\        5--24 mg/kg + Oral\                   CYP2B6, CYP2C9 and CYP2C19 to\                      decreased exposure to\                                    for both components. Avoid\
                         a fixed dose combination\          lumefantrine\                         active metabolite dihydroartemisinin\               artemether/lumefantrine and\                              concurrent use.\
                         with lumefantrine.\                29--144 mg/kg twice\                  (DHA). t ~1/2~ for artemether and\                  potential loss of efficacy.\                              [PIs]{.ul}: Potential ↑AUC for\
                         \                                  daily for 3 days.\                    DHA \~1--2 hrs, but up to 7 hrs.\                   ↓ Artemether, DHA, and\                                   lumefantrine. Monitor use\
                         2. Intramuscular artemether\       \                                     Lumefantrine also undergoes\                        lumefantrine AUC by 89%, 85%,\                            closely.
                         as an alternative for severe\      Intramuscular\                        metabolism via CYP3A4 to active\                    and 68% respectively.\                                    
                         malaria.                           artemether: 3.2 mg/kg.                metabolite desbutyl-lumefantrine.\                  \                                                         
                                                                                                  t ~1/2~ \~3 days.                                   Avoid concurrent use.                                     

  Artesunate             1\. Uncomplicated\                 Oral: 4 (2--10) mg/kg/day\            Hydrolyzed rapidly to DHA by gut\                   No published drug interaction\                            [NVP, PIs]{.ul}: Potential ↑ AUC.\
                         *P. falciparum*\                   once a day for 3 days.\               esterases with some contribution\                   data but significant reduction\                           Monitor if co-administered.
                         malaria in combination with\       \                                     from CYP2B6. Very little excreted\                  in DHA (the active metabolite)\                           
                         amodiaquine or\                    Parenteral: 2.4 mg/kg\                unchanged in the urine, and inactive\               due to CYP450 metabolism may\                             
                         mefloquine or sulfadoxine/\        unless \<25kg/5 years\                metabolites are excreted in the bile.\              result in reduced efficacy.\                              
                         pyrimethamine.\                    then 3 mg/kg.                         t ~1/2~ of artesunate and DHA is \<2 hrs.           \                                                         
                         \                                                                                                                            Monitor closely if concurrent use.                        
                         2. Parental artesunate\                                                                                                                                                                
                         for severe malaria.                                                                                                                                                                    

  Atovaquone/\           1\. Prophylaxis of malaria.\       Prophylaxis:\                         Converted by CYP2C19 to cycloguanil\                Concurrent use may result in\                             [EFV, NVP]{.ul}: ↓ conc. of\
  Proguanil              \                                  Atovaquone 250 mg/\                   and 4-chlorophenylbiguanide.\                       reduced atovaquone plasma\                                atovaquone, proguanil and\
                         2. Uncomplicated malaria\          proguanil 100 mg once\                Atovaquone is mostly excreted\                      levels and increase rifampin\                             possibly cycloguanil. Avoid\
                         in non-endemic regions\            daily 1 day prior to\                 unchanged via fecal route, while\                   plasma levels\                                            concurrent use.\
                         when primary regimens are\         entering endemic area,\               proguanil can have renal excretion\                 Atovaquone plasma conc.↓ 50%\                             [PIs]{.ul}: Potential ↓ atovaquone\
                         not available.                     during stay, and for\                 up to 60%. Atovaquone t ~1/2~: adults\              \                                                         AUC. Monitor use closely.
                                                            7 days after return.\                 \~2 to 3 days, pediatric \~1 to 2 days.\            Avoid concurrent use.                                     
                                                            \                                     Proguanil t ~1/2~ \~12 to 22 hrs.                                                                             
                                                            Treatment: Atovaquone\                                                                                                                              
                                                            1000 mg/proguanil\                                                                                                                                  
                                                            400 mg once daily for\                                                                                                                              
                                                            3 days.                                                                                                                                             

  Chloroquine            1\. Uncomplicated malaria\         Initial dose of 10 mg/kg,\            Metabolized by CYP2C8 and\                          ↓ Chloroquine level might be\                             [EFV]{.ul}: Potential for QT\
                         due to *P.vivax, P. malariae,*\    followed by 10 mg/kg\                 CYP3A4 to active metabolite\                        expected.\                                                prolongation.\
                         *P. ovale and P. knowlesi.*        on the second day and\                monodesethychloroquine. Slow\                       \                                                         Monitor if co-administered.
                                                            5 mg/kg on the third day.             elimination via the kidney for both\                Monitor closely if concurrent use.                        
                                                                                                  chloroquine and its active metabolite\                                                                        
                                                                                                  with t ~1/2~ \~ 4--12 days.                                                                                   

  Clindamycin            1\. Severe or uncomplicated\       10 mg/kg twice daily\                 Extensive metabolism via CYP3A4\                    No significant drug interaction\                          No significant drug\
                         malaria in combination with\       for 7 days.                           and intestines to N-demethyl and\                   data.                                                     interaction data.
                         artesunate or quinine.\                                                  sulfoxide metabolites. Excretion of\                                                                          
                         \                                                                        active drug is via urine (10%) and\                                                                           
                         2. Preferred:\                                                           feces (4%). t ~1/2~ is \~ 2--3.5 days.                                                                        
                         Uncomplicated\                                                                                                                                                                         
                         *P. falciparum* malaria in\                                                                                                                                                            
                         combination with quinine\                                                                                                                                                              
                         for first trimester of\                                                                                                                                                                
                         pregnancy.                                                                                                                                                                             

  Dihydroartemisinin/\   1\. Uncomplicated\                 4 (2--10) mg/kg\                      Piperaquine induces CYP2E1,\                        Concurrent use may result\                                [EFV, NVP]{.ul}: ↓plasma conc.\
  piperaquine            *P. falciparum or P. vivax*\       dihydroartemisinin\                   inhibits CYP3A4 and CYP2C19\                        in decreased exposure of\                                 for both components.\
                         malaria.\                          and 18 (16--27) mg/kg\                and is a substrate of CYP3A4\                       piperaquine. *In vitro* metabolism\                       Potential for QT\
                         \                                  piperaquine once daily\               (primary), CYP2C9, and CYP2C19.\                    by CYP3A4 increased for\                                  prolongation with EFV.\
                         2. Follow up oral treatment\       for 3 days if weighing\               Dihydroartemisinin is an inhibitor of\              piperaquine.\                                             Monitor use closely.\
                         in severe malaria.                 ≥ 25 kg. If under 25 kg,\             CYP1A2 and substrate of UGT1A9\                     \                                                         [PIs]{.ul}: ↓piperaquine\
                                                            then 4 (2.5--10) mg/kg\               and UGT2B7. t ~1/2~ of dihydroartemisinin\          Consider alternatives and\                                exposure.\
                                                            dihydroartemisinin\                   \~1 hr, while piperaquine \~13--28 days.            monitor closely if concurrent use.                        Monitor if co-administered.
                                                            and 24 (20--32) mg/kg\                                                                                                                              
                                                            piperaquine once daily\                                                                                                                             
                                                            for 3 days.                                                                                                                                         

  Doxycycline            1\. Prophylaxis of malaria.\       Prophylaxis: 100 mg\                  50% hepatic metabolism with\                        Concurrent use may result\                                No significant drug\
                         \                                  daily beginning 1 day\                extensive enterohepatic cycling\                    in reduced doxycycline\                                   interaction data.
                         2. In combination with\            prior to travel, during\              Eliminated renally (35--45%) and\                   serum conc. and potential\                                
                         quinine or artesunate as\          travel, and for 4 weeks\              high conc. of the active drug are\                  loss of doxycycline efficacy.\                            
                         follow up oral treatment in\       after return.\                        also excreted in feces and urine. t ~1/2~\          Doxycycline AUC ↓ by 40%.\                                
                         severe malaria.\                   \                                     \~15--24 hrs.                                       \                                                         
                         \                                  Treatment: Doxycycline\                                                                   Consider alternatives and\                                
                         3. Uncomplicated\                  100 mg twice daily for\                                                                   monitor closely if concurrent use                         
                         falciparum malaria in\             7 days                                                                                                                                              
                         combination with quinine/\                                                                                                                                                             
                         artesunate.                                                                                                                                                                            

  Mefloquine             1\. Prophylaxis of malaria.\       Prophylaxis: 250 mg\                  Metabolized via CYP3A4 to largely\                  Concurrent use results in\                                [EFV]{.ul}: Potential for QT\
                         \                                  once weekly beginning\                inactive metabolites. Undergoes\                    decreased mefloquine exposure\                            prolongation.\
                         2. Uncomplicated\                  1 week prior to travel,\              enterohepatic cycling. Minimal renal\               and potential loss of efficacy.\                          \
                         *P. falciparum* malaria\           continuing weekly and\                excretion and excretion is primarily via\           Mefloquine AUC ↓ 68%.\                                    Monitor if co-administered.
                         in combination with\               for 4 weeks after return.\            the bile and feces. t ~1/2~ \~13 to 30 days.        \                                                         
                         artesunate.                        \                                                                                         Avoid concurrent use.                                     
                                                            Treatment: 8.3 (5--11)\                                                                                                                             
                                                            mg/kg once daily for\                                                                                                                               
                                                            3 days.                                                                                                                                             

  Primaquine             1\. As an alternative for\         14 day course for\                    Transformed via CYP2C19, CYP2D6\                    No significant drug interaction\                          No significant drug interaction\
                         primary prophylaxis of all\        relapse prevention and\               and CYP3A4 to active metabolite\                    data.                                                     data.
                         malaria.\                          radical treatment:\                   8-(3-carboxyl-1-methylpropylamino)-\                                                                          
                         \                                  0.25 mg/kg.\                          6-methoxyquinoline and inactive\                                                                              
                         2. Radical cure of *P. vivax*\     Increase to 0.5 mg/kg\                metabolite carboxyprimaquine.\                                                                                
                         or *P. ovale* malaria.\            for frequently relapsing\             Excretion mainly via the bile and feces\                                                                      
                         \                                  and for primary\                      but can be excreted unchanged in\                                                                             
                         3. In combination with\            prophylaxis. Maximum\                 urine. t ~1/2~ \~ 4--7 hrs with longer half-life\                                                             
                         ACT or chloroquine for\            of 30 mg/day.\                        (15--16 hrs) for the inactive metabolite.                                                                     
                         presumptive anti-relapse\          \                                                                                                                                                   
                         therapy for extensive\             Single dose as an anti-\                                                                                                                            
                         exposure to *P. vivax/P. ovale.*   gametocyte medication:\                                                                                                                             
                                                            0.25 mg/kg.                                                                                                                                         

  Quinine                1\. Preferred:\                    Oral: 650 mg (or two\                 Metabolism via CYP3A4 (primary),\                   Concurrent use is associated\                             [EFV, RPV, PIs]{.ul}: Potential for\
                         Uncomplicated *P. falciparum*\     324-mg capsules\                      CYP2C9, CYP1A2 and CYP2D6\                          with a significant decrease in\                           QT prolongation. Monitor if\
                         malaria in combination\            (648 mg)) 3 times daily\              to several metabolites including\                   quinine exposure and 5-fold\                              co-administered.\
                         with clindamycin for first\        for 3 or 7 days.\                     active metabolite 3-hydroxyquinine.\                recrudescence rate. Quinine\                              [NVP]{.ul}: ↓plasma conc. Avoid\
                         trimester of pregnancy.\           \                                     Excretion via the kidney (20%\                      AUC ↓ 75% to 85%.\                                        concurrent use.
                         \                                  Parental: Loading\                    unchanged) but potentially small\                   \                                                         
                         2. Parental quinine for\           dose of 20 mg\                        amounts via the bile and saliva. t ~1/2~ \~\        Avoid concurrent use.                                     
                         severe malaria.                    salt/kg followed by\                  10 to 20 hrs.                                                                                                 
                                                            maintenance dose of\                                                                                                                                
                                                            10 mg salt/kg every\                                                                                                                                
                                                            8 hrs.                                                                                                                                              

  Sulfadoxine/\          1\. Intermittent prophylaxis\      Single administration\                Metabolism via acetylation (60%),\                  No significant drug interaction\                          No significant drug\
  pyrimethamine          in pregnant women in\              of at least 25/1.25\                  glucuronidation (10%) and\                          data.                                                     interaction data.
                         1 ^st^/2 ^nd^ pregnancy and\       (25--70 / 1.25--3.5)\                 conjugation. There is about 30% renal\                                                                        
                         infants in areas of mid-\          mg/kg sulfadoxine\                    excretion of unchanged drug for both\                                                                         
                         high intensity malaria\            /pyrimethamine given\                 sulfadoxine and pyrimethamine. t ~1/2~\                                                                       
                         transmission.\                     as a single dose on\                  \~9.5 days and for pyrimethamine\                                                                             
                         \                                  day 1.                                \~2.5 --6 days.                                                                                               
                         2. In combination with\                                                                                                                                                                
                         atovaquone for seasonal\                                                                                                                                                               
                         malaria chemoprevention\                                                                                                                                                               
                         in young children in areas\                                                                                                                                                            
                         of high intensity malaria\                                                                                                                                                             
                         transmission.                                                                                                                                                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

t ~1/2~, elimination half-life; EFV, efavirenz; NVP, nevirapine; AZT/ZVD, zidovudine; DHA, dihydroartemisinin; PI, protein inhibitors; AUC, area under the curve; ACT, artemisinin-based combination therapy; RPV, rilpivirine.

Discussion
==========

This case demonstrates the diagnostic and treatment challenges encountered when managing patients with advanced HIV and intercurrent infections. Protracted high-grade fevers are not an uncommon feature of TBM, even after appropriate anti-tuberculous treatment has been commenced, and it is important to remain vigilant for co-infections. Co-infection with HIV-TB-malaria is well recognized ^[@ref-4]^; however, to our knowledge this is the first published case of HIV-TBM-malaria co-infection.

Due to the potential overlap in symptoms and signs between TBM and malaria (fever, confusion, reduced level of consciousness, seizures, sepsis), access to accurate parasitological diagnostics is essential. Light microscopy (Giemsa stain) remains the gold standard parasitological diagnostic, but the World Health Organization (WHO) recommends immunochromatographic rapid diagnostic testing (RDT) in settings with limited laboratory facilities ^[@ref-6]^. RDTs---which detect *Plasmodium* antigens such as PfHPR2, *Plasmodium* lactate dehydrogenase (pLDH) or plasmodial aldolase---are the backbone of expanding access to malaria diagnostics in resource-limited settings. Since their introduction in the late 1990s, the number of RDTs available, and the scale of their use, has increased rapidly. A meta-analysis of 74 studies assessing accuracy of PfHRP-2 RDTs for diagnosis of uncomplicated *P. falciparum* malaria in endemic settings reported average sensitivity and specificity (95% CI) of 95.0% (93.5-96.2%) and 95.2% (93.4-99.4%), respectively ^[@ref-7]^. However RDTs do have several limitations: poor sensitivity at low parasite densities; susceptibility to the prozone effect (PfHRP2-detecting RDTs); false-negative results due to PfHRP2 gene deletions; false-positive results caused by other infections, and susceptibility to heat and humidity ^[@ref-8]^. The largest problem historically has been poor manufacturing quality, which the World Health Organization (WHO) malaria product testing programme has addressed. However, Vaxpert does not participate in this WHO quality assurance program. As demonstrated by this case, false negatives can occur.

The WHO recommends treatment with an artemisinin derivative for both uncomplicated (oral artemisinin combination therapy (ACT) for 3 days) and complicated falciparum malaria infections (intravenous or intramuscular artesunate for at least 24 hours and until the patient can tolerate oral medications, at which stage 3 days of ACT should be completed) ^[@ref-6]^. It is recommended that a lipid rich meal is eaten prior to taking lumefantrine to optimise absorption. Despite the recognition of potential DDIs between first-line anti-malarial drugs and rifampicin, no treatment guidelines currently exist for managing patients with TB/malaria co-infection. The WHO states that there is currently a lack of evidence to recommend dosage modifications but advises clinicians of increased risk of recrudescent infections due to DDIs in co-infected patients ^[@ref-6]^.

In a DDI study in HIV-infected Ugandans to investigate the pharmacokinetics of artemether, dihydroartemisinin (DHA) and lumefantrine during rifampicin intake, co-administration with rifampicin resulted in a significantly lower exposure (area under the curve between 0 and 12 hours post-dosing) to artemether (89% lower) and DHA (85% lower) ^[@ref-9]^. Co-administration of artemether-lumefantrine and rifampicin should therefore be avoided. There are no published studies examining concomitant administration of IV artesunate and rifampicin. However, as DHA (the active metabolite of artesunate) is metabolized by CYP450 enzymes ( [Table 1](#T1){ref-type="table"}), there is a theoretical risk that co-administration with rifampicin would result in reduced plasma DHA concentrations and a reduction in efficacy ^[@ref-5]^. Oral agents may undergo metabolism in the gut and the liver prior to reaching the systemic circulation, but intravenous drugs are directly administered to the systemic circulation and so reductions in DHA exposure with intravenous artesunate could be potentially of lower magnitude than what was seen with oral artemether.

Similarly, the bioavailability of quinine---metabolized almost exclusively via CYP450 (CYP3A4 and CYP2C19) enzymes---is significantly reduced when co-administered with rifampicin and has been associated with a clinically significant reduction in efficacy. Adults treated for uncomplicated falciparum malaria were randomized to receive oral quinine either alone or in combination with rifampin; recrudescence rates were five times higher (15/23; 65%) in the rifampicin arm than those treated with quinine alone (3/25; 12%, *P*\<0.001) ^[@ref-11]^. It is recommended that for patients already receiving rifampicin, quinine doses should be increased. However, to date, no guidance on dose-adjustment strategies have been published, and although it is advised that therapeutic drug monitoring may be useful, this is not feasible in most parts of the world where co-infection occurs ^[@ref-5]^.

A range of anti-malarial drugs used in the treatment of non-severe malaria and for prophylaxis also have documented DDIs with rifampicin including: atovaquone; chloroquine; piperaquine; mefloquine and doxycycline ( [Table 1](#T1){ref-type="table"}). As no clinical guidelines currently exist regarding dose modification, these drugs should be used with caution in patients concurrently receiving rifampicin.

Many antiretrovirals also interact with the CYP450 system ( [Table 1](#T1){ref-type="table"}). For example, co-administration with efavirenz reduces exposure to the active components of artemether and lumefantrine 46% and 21%, respectively. However, the net induction effects of the use of both rifampicin and efavirenz on antimalarial compounds has not been quantified. Similarly, protease inhibitors are potent CYP450 inhibitors and their combined effect with rifampicin induction is unknown.

This case highlighted the difficulty in managing co-infected patients and the lack of informed treatment options. New anti-malarial medication development have the potential to offer improved potency, tolerability, and shorter treatment duration but drug- drug interactions are likely to persist. In cases of suspected significant interactions, healthy volunteer studies may play a role in informing management as efficient study designs allow for small sample sizes. Our group has also employed building in pharmacokinetic sampling and analysis into existing clinical trials. Coupling sparse or opportunistic sampling with pharmacokinetic modeling and simulation can allow for increased precision in dose selection.

Conclusions
===========

In conclusion, patients with HIV-TBM-malaria co-infection present a number of management challenges. The potential symptom overlap in clinical presentation means that clinicians must remain vigilant for co-infection and access to reliable parasitological diagnostics is imperative. As malaria RDT use continues to expand, it is essential that clinicians are aware of the potential for false negative results. Therapeutic options for TB-malaria co-infection are limited due to DDIs. There is both an urgent need for the development of new anti-malarial drugs which do not interact with rifampicin and for pharmacokinetic studies to guide dose modification of existing anti-malarial drugs to inform clinical practice guidelines.

Data availability
=================

*All data underlying the results are available as part of the article and no additional source data are required.*

Consent
=======

The Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related Meningitis study protocol was approved by Ugandan and Minnesota IRBs. Written informed consent from the patient's next of kin was given for publication of that patient's clinical details as the patient himself lacked the mental capacity to consent.

We thank the study participant and his family, and gratefully acknowledge the support offered by the clinical trial staff.
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The table summarising the drug interactions is very helpful.

For those who may be less familiar with managing such patients, was the case unusual? Is it common to present with TB meningitis five months into therapy where there has been apparent adherence?

Was the ceftriaxone discontinued once the positive TB result from CSF was obtained? (I presume so, but it is not explicitly stated)

I would be interested to know about any follow-up post discharge. Was anything done differently, for example support for adherence etc?

The conclusion finishes with reiterating the 'urgent need for the development of new anti-malarial drugs which do not interact with rifampicin and for pharmacokinetic studies to guide dose modification of existing anti-malarial drugs to inform clinical practice guidelines' -- I entirely agree with this statement, but given the challenges and diversity in the population in question which has been described, I would also have liked a couple of sentences in the discussion  about how such studies could best be designed. What would be ideal? Logistically, how could such a population be drawn together to provide meaningful data? Do healthy volunteer studies have a part to play here? Are the authors involved in any existing work to try and address some of these gaps? Are they aware of any other work that is ongoing?

Minor points

CSF opening pressure should be measured in cm CSF, not cm H20.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
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This is a well written case report highlighting an important issue for clinicians practicing in areas where malaria, HIV and TB are endemic.

Prompted by a case they saw, the authors helpfully summarise the potential DDIs between anti-malarial medications and anti-tuberculous and anti-retroviral medications in common use. This issue deserves publication in its current form with consideration of a few minor issues.

I have only minor comments to make.

-Was the ceftiaxone stopped as soon as the Xpert was positive? This would be appropriate given the low pre-test probability of bacterial meningitis (2 week history) and the identification of a an alternative definite diagnosis. It might be helpful to remind readers that \'finishing the course\' of an antibiotic in this situation is not necessary and can cause harm.

-It would be helpful to confirm that the Xpert MTB/RIF Ultra confirmed rifampicin sensitivity as the patient was clearly at risk of DR-TB.

-It would be worth pointing out that it takes around 2 weeks for the full effects of enzyme induction by rifampicin to be felt. If malaria is diagnosed at a similar time to TB, as in this case, the initial effects of enzyme induction might be limited, but increase over time which would increase the challenge of finding the appropriate dose.

\- It is never a bad thing to remind people of the need for a lipid meal before taking lumafantrine in order to achieve adequate absorption, something which is often neglected.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
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